Due to the demands of the Danish Medicines Agency, the production of medical cannabis will in the first phase be
based upon import of raw materials (THC and CBD)
The CiBiD Group has entered into a cooperation agreement with HB Medical about production of medical cannabis – produced under GMP. This agreement permits us to offer a high quality intermediate product to pharmacies which both patients and authorities can have confidence in.
The CiBiD Group will continuously evaluate the opportunities and the value of cooperating with international pharma companies regarding development of new medical products based on cannabis.
As some conservatism is anticipated among Danish doctors who are to prescribe the product and take responsibility for the treatment with medical cannabis, a slow start is expected in this market segment.
The CiBiD Group will – together with patient associations – regularly arrange conferences for doctors and other stakeholders, including politicians, about the use and evidence of medical cannabis.